{"id":"W2142482664","doi":"10.1086/590566","title":"Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria","year":2008,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":460,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"National Institutes of Health; Astellas Pharma; Gilead Sciences; Steadman Philippon Research Institute; Eisai; Pfizer; Amgen","keywords":"Medicine; Clinical trial; Coccidioides; Coccidioides immitis; Intensive care medicine; Antifungal; Cryptococcus neoformans; Aspergillosis; Cryptococcosis; Cancer; Histoplasma; Disease; Histoplasmosis; Pathology; Immunology; Internal medicine; Histoplasma capsulatum; Dermatology; Biology; Microbiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1037487,0.002000076,0.01384185,0.00770325,0.0007852359,0.003918665,0.003238961,0.004858517,0.001959688],"category_scores_gemma":[0.1860879,0.000723467,0.006223542,0.007821042,0.001929151,0.002892076,0.002240916,0.003298739,0.0005505067],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004879363,"about_ca_system_score_gemma":0.01185064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001564589,"about_ca_topic_score_gemma":0.002436573,"domain_scores_codex":[0.8532315,0.08316315,0.04662789,0.00270927,0.01332467,0.0009434985],"domain_scores_gemma":[0.7946026,0.1580814,0.02681739,0.003052544,0.0156389,0.001807153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001932911,0.0001571823,0.003806554,0.2969714,0.005689991,0.0002340609,0.0004602712,0.000741034,0.0004180405,0.007482152,0.03073716,0.6513692],"study_design_scores_gemma":[0.005117984,0.001693236,0.02899461,0.5142707,0.02259994,0.001962037,0.0007698967,0.001821373,0.001102421,0.01738997,0.4040099,0.0002678752],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003759184,0.9925914,0.001436073,0.002549781,0.0005605908,0.001391341,0.0002665147,0.00001715648,0.0008111692],"genre_scores_gemma":[0.01520513,0.9469569,0.0161924,0.005514591,0.001291185,0.01317907,0.0009621485,0.00002828397,0.0006701858],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1037487,"threshold_uncertainty_score":0.5486823,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4496080110103085,"score_gpt":0.5926173956961437,"score_spread":0.1430093846858352,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}